Information Provided By:
Fly News Breaks for November 13, 2019
Nov 13, 2019 | 12:36 EDT
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $19 from $27 citing reduced revenue estimates following the company's Q3 results. The company reported Giapreza U.S. net sales of $5.7M, below the analyst's estimate of $6.7M. However, he forecasts Q4 volume will pick up as Giapreza sales "appear to be seasonal due to the flu season." White keeps a Buy rating on La Jolla shares.
News For LJPC From the Last 2 Days
There are no results for your query LJPC